US 11,911,509 B2
Pharmaceutical composition comprising Lenvatinib mesylate
Luis Nogueiras Nieto, Sant Boi de Llobregat (ES); Lisardo Alvarez Fernandez, Sant Boi de Llobregat (ES); Jose Velada Calzada, Nijmegen (NL); and Rohit Kumar, Sant Boi de Llobregat (ES)
Assigned to Synthon B.V., Nijmegen (NL)
Appl. No. 16/603,031
Filed by Synthon B.V., Nijmegen (NL)
PCT Filed Apr. 4, 2018, PCT No. PCT/EP2018/058629
§ 371(c)(1), (2) Date Oct. 4, 2019,
PCT Pub. No. WO2018/185175, PCT Pub. Date Oct. 11, 2018.
Claims priority of application No. 17164761 (EP), filed on Apr. 4, 2017.
Prior Publication US 2020/0188380 A1, Jun. 18, 2020
Int. Cl. A61K 31/47 (2006.01); A61K 47/02 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); A61K 9/16 (2006.01); A61K 9/00 (2006.01)
CPC A61K 9/1694 (2013.01) [A61K 9/0046 (2013.01); A61K 31/47 (2013.01); A61K 47/02 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A pharmaceutical composition comprising (i) a therapeutically effective dose of Lenvatinib mesylate and (ii) sodium bicarbonate in a range of from 20 to 55%, by weight based on the total weight of the composition, wherein the weight ratio of Lenvatinib mesylate to sodium bicarbonate ranges from 1:1.5 to 1:5.